Concord Wealth Partners Cti Biopharma Corp Transaction History

Concord Wealth Partners

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 20, 2022	SELL	$1.9 - $5.23 $5 - $15	-3 Closed	0 $0
Q4 2021 Jan 21, 2022	BUY	$1.44 - $2.86 $4 - $8	3 New	3 $0
Q1 2021 May 13, 2021	SELL	$2.68 - $3.8 $24 - $34	-9 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $22 - $34	9 New	9 $0

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.